InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,433.43
(
0.03%
)
US TECH 100
19,184.80
(
0.09%
)
Dow Jones
38,555.49
(
-0.09%
)
Brent Oil
82.85
(
0.88%
)
Bitcoin
65,389.39
(
-1.88%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 164

Saturday, 05/19/2018 9:08:47 AM

Saturday, May 19, 2018 9:08:47 AM

Post# of 438
APTO has two early-stage oncology with excellent commercial potential waiting to ENTER the clinic.

CEO may be the most hands-on chief in small cap biotech.

APTO-253 is an AML treatment that is on FDA clinical hold for manufacturing issues. Peak sales could be in the range of ~$550mn

CG806 is a pre-clinical drug with a potential in B-cell. It could address a $1B opty

Cash runway is into Q2/2019.

In 2017, it took an average:
$5mn to run a PH1 oncology study
$11mn to run a PH2 oncology study
$22mn to run a PH3 oncology study

APTO needs to raise ~$200mn to get across the finish line.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up